0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessIn the phase 3 RESORCE trial, regorafenib improved OS compared with placebo in patients with unresectable HCC who progressed during sorafenib treatment. The most common regorafenib-related adverse events were hand-foot skin reaction, diarrhea, fatigue, hypertension, and anorexia, consistent with the known safety profile of regorafenib. We present an updated OS analysis from RESORCE, nearly 2 years after the primary analysis.
D. Waldschmidt, Alessandro Granito, Philippe Merle, Yi‐Hsiang Huang, G. Bodoky, Osamu Yokosuka, Olivier Rosmorduc, Валерий Владимирович Бредер, René Gerolami, Gianluca Masi, P.J. Ross, Susan Quinn, Tianqiang Song, JP Bronowicki, Isabelle Olivier-Hourmand, Masatoshi Kudo, MA LeBerre, Annette Baumhauer, Gudrun Meinhardt, Guorong Han, Jordi Bruix (2019). Overall Survival (OS) Update: 2-year follow-up from the phase-3 RESORCE trial of Regorafenib for patients with hepatocellular carcinoma (HCC) progressing on Sorafenib. , DOI: https://doi.org/10.1055/s-0039-1695314.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2019
Authors
21
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1055/s-0039-1695314
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
